These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 37283287)
21. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. Necchi A; Raggi D; Giannatempo P; Marandino L; Farè E; Gallina A; Colecchia M; Lucianò R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Dittamore R; Liu Y; Davicioni E; Ross JS; de Jong JJ; Briganti A; Montorsi F; Gibb EA Eur Urol Oncol; 2021 Dec; 4(6):1001-1005. PubMed ID: 32417369 [TBL] [Abstract][Full Text] [Related]
22. Successful treatment of advanced muscle-invasive bladder cancer with the combined therapy of toripalimab and chemotherapy: a case report. Dian X; Kun L; Xin W; SongBai Y; Qi L; Liangkuan B Anticancer Drugs; 2022 Nov; 33(10):1156-1162. PubMed ID: 35946545 [TBL] [Abstract][Full Text] [Related]
23. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285 [TBL] [Abstract][Full Text] [Related]
24. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer. Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422 [TBL] [Abstract][Full Text] [Related]
25. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Benítez R; Yu K; Sirota M; Malats N; Pineda S Front Immunol; 2023; 14():986598. PubMed ID: 36817478 [TBL] [Abstract][Full Text] [Related]
26. Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer. Maas M; Rausch S; Guttenberg T; Seiler R; Hennenlotter J; Oo HZ; Fazli L; Kühs U; Gakis G; Stenzl A; Schwentner C; Black PC; Todenhöfer T Eur Urol Focus; 2022 May; 8(3):718-727. PubMed ID: 33962883 [TBL] [Abstract][Full Text] [Related]
27. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669 [TBL] [Abstract][Full Text] [Related]
28. Stromal LAG-3 Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859 [TBL] [Abstract][Full Text] [Related]
29. Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy. Cao W; Ma E; Zhou L; Yuan T; Zhang C World J Surg Oncol; 2017 Mar; 15(1):66. PubMed ID: 28320388 [TBL] [Abstract][Full Text] [Related]
30. FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. Neuzillet Y; van Rhijn BW; Prigoda NL; Bapat B; Liu L; Bostrom PJ; Fleshner NE; Gallie BL; Zlotta AR; Jewett MA; van der Kwast TH Virchows Arch; 2014 Aug; 465(2):207-13. PubMed ID: 24880661 [TBL] [Abstract][Full Text] [Related]
31. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523 [TBL] [Abstract][Full Text] [Related]
32. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092 [TBL] [Abstract][Full Text] [Related]
33. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328 [TBL] [Abstract][Full Text] [Related]
34. Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis. Han Y; Liu X; Ye H; Tian Y; Ji Z World J Surg Oncol; 2020 Nov; 18(1):310. PubMed ID: 33243261 [TBL] [Abstract][Full Text] [Related]
35. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391 [TBL] [Abstract][Full Text] [Related]
36. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy Fan B; Zheng X; Wang Y; Hu X Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269 [No Abstract] [Full Text] [Related]
37. Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. Ma J; Zhou Q; Xu W; Li C; Wang H; Zhai Z; Zhang Y; Wahafu W Int Immunopharmacol; 2023 Jan; 114():109535. PubMed ID: 36527880 [TBL] [Abstract][Full Text] [Related]
38. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615 [TBL] [Abstract][Full Text] [Related]
39. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway. He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915 [TBL] [Abstract][Full Text] [Related]
40. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]